Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
CAMBRIDGE, Mass., Nov. 21, 2016 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert A. Copeland, Ph.D., has been named a fellow of the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society. Fellows are elected by the association’s membership in recognition of their efforts toward advancing science applications that are deemed scientifically or socially distinguished. Dr. Copeland will be recognized at a ceremony on February 18 at the 2017 AAAS Annual Meeting in Boston, Mass.
“I am honored to be recognized by AAAS and join the ranks of such an accomplished group of scientists,” said Robert A. Copeland, Ph.D. “I am extremely fortunate to have worked with many talented researchers and colleagues in my years at Epizyme who have contributed greatly to the work recognized by AAAS and I look forward to our continued leadership in the field.”
Dr. Copeland was chosen by the Section on Biological Sciences for his insights contributing to small molecule therapeutics and the discovery that a heterozygous enzymatic activity between a wild-type and mutant enzyme contributes to oncogenesis. During his career, he has contributed to drug discovery and development efforts across a wide range of therapeutic areas leading to three approved drugs and nearly 20 candidates entering human clinical trials, has contributed more than 200 publications in the scientific literature, holds 13 issued U.S. patents and has authored 5 books in the areas of protein science and enzymology. Under Dr. Copeland’s leadership, Epizyme discovered a number of novel epigenetic targets and developed three first-of-their-kind potential new medicines that have advanced into the clinic, including tazemetostat, an EZH2 inhibitor being evaluated across multiple cancer indications.
“Bob’s achievements have contributed greatly to the scientific community’s understanding of the epigenetic mechanisms driving cancer development,” said Robert Bazemore, President and CEO, Epizyme. “His insights and leadership have helped Epizyme pioneer the field of epigenetics and the discovery and development of tazemetostat, the most advanced EZH2 inhibitor in the clinic today.”
The full list of awardees may be found in the November 25 issue of the journal, Science.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit www.epizyme.com.
About AAAS
The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science (www.sciencemag.org) as well as Science Translational Medicine, Science Signaling, a digital, open-access journal, Science Advances, Science Immunology, and Science Robotics. AAAS was founded in 1848 and includes nearly 250 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world. The non-profit AAAS (www.aaas.org) is open to all and fulfills its mission to “advance science and serve society” through initiatives in science policy, international programs, science education, public engagement, and more. For the latest research news, log onto EurekAlert! (www.eurekalert.org), the premier science-news Web site, a service of AAAS. See www.aaas.org.
Epizyme Contact: Julie DiCarlo, (617) 306-5823 [email protected]
